News
Telix to Acquire ITM in US$1.65 Billion Radiopharmaceutical Deal
ITM’s late-stage pipeline is expected to complement Telix’s existing portfolio and includes ITM-11, a novel therapeutic candidate for the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
imphoenix82
- September 21, 2026
- 0 Comments
- 164 Views
-
